SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1009Thanks for posting the SSB analysis. Does anybody else find SSB's use of a 1fred hayes-11/16/2002
1008Eur J Neurosci 2002 Nov;16(9):1751-1760 Overexpression of corticotropin-releasscaram(o)uche-11/15/2002
1007SSB's report on the P3 data: Neurocrine Biosciences (NBIX) NBIX: Positive Pmopgcw-11/14/2002
1006Neurocrine Biosciences Reports Positive Results From First Phase III Clinical Trscaram(o)uche-11/14/2002
1005SSB pt 2: We summarize detailed data of some of the key efficacy endpoints measmopgcw-11/9/2002
1004SSb: October 31, SUMMARY 2002 * Yesterday, after market close, mopgcw-11/9/2002
1003Sanofi shares hit by concerns of rival sleeping pill LONDON, Nov 6 (Reuters) - mopgcw-11/6/2002
1002RE: CC Indication that two new IND (in '03 at least one) will most likely Miljenko Zuanic-10/31/2002
1001snippet...... <i>The lead clinical compound under Neurocrine's CRF prscaram(o)uche-10/30/2002
1000From SEPR: Press Release Source: Sepracor Inc. Sepracor Announces Third QuartMiljenko Zuanic-10/22/2002
999Message 18136837 (interesting comments, from the real world)scaram(o)uche-10/21/2002
998"Giving their clients bad advice" Doing her job and getting paid for Threshold-10/18/2002
997That Taisho will kept Asia market right.Miljenko Zuanic-10/14/2002
996<i>It is worse than I expected.</i> Miljenko, What did you expect?jayhawk969-10/14/2002
995It is worse than I expected. [eom]Miljenko Zuanic-10/14/2002
994Neurocrine Biosciences and Taisho Pharmaceutical Announce Agreement RestructurinIcebrg-10/14/2002
993If nbix gets chronic use label OR elderly label OR MR succeeds, how could indiplkeokalani'nui-10/10/2002
992Ah, old good Sturza. Not only that he can not pick longs, but he is lousy with sMiljenko Zuanic-10/10/2002
99111:34 ET NBIX Neurocrine Biosci weak following boutique firm note (39.13 -0.4Doc Bones-10/10/2002
990Thanks for sharing that. The JCI article was disturbing given all of the trialsmopgcw-10/9/2002
989Received respond from NBIX regards the article in JCI. ""We have no Miljenko Zuanic-10/9/2002
988Are we at point when another setback for NBIX APL technology is for real? jci.oMiljenko Zuanic-10/7/2002
987Clin Immunol 2002 Aug;104(2):105 Persistence of immune responses to altered anscaram(o)uche-9/18/2002
986Always a pleasure to read: messages.yahoo.commopgcw-8/28/2002
985IL-4's sister toxin....... Friday August 16, 7:00 am Eastern Time Press Relscaram(o)uche-8/16/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News